Voya Investment Management LLC Sells 187,388 Shares of Heartflow, Inc. $HTFL

Voya Investment Management LLC cut its holdings in shares of Heartflow, Inc. (NASDAQ:HTFL – Free Report) by 25.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 545,795 shares of the company’s stock after selling 187,388 shares during the quarter. Voya Investment Management LLC owned approximately 0.63% of Heartflow worth $27,153,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in HTFL. GAMMA Investing LLC grew its position in shares of Heartflow by 75.1% during the third quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock worth $32,000 after purchasing an additional 275 shares in the last quarter. IFP Advisors Inc raised its stake in Heartflow by 844.7% during the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after purchasing an additional 718 shares during the period. Allworth Financial LP lifted its holdings in Heartflow by 116.4% in the 3rd quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after purchasing an additional 616 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Heartflow in the 2nd quarter worth approximately $53,000. Finally, Essential Partners LLC bought a new position in Heartflow in the 1st quarter worth approximately $57,000.

Insider Activity at Heartflow

In other news, CEO John Farquhar sold 38,900 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $55.74, for a total transaction of $2,168,286.00. Following the sale, the chief executive officer directly owned 251,983 shares in the company, valued at approximately $14,045,532.42. This represents a 13.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikram Verghese sold 3,587 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $53.15, for a total transaction of $190,649.05. Following the sale, the chief financial officer owned 149,587 shares in the company, valued at $7,950,549.05. This represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 323,936 shares of company stock valued at $16,355,191 over the last 90 days. 7.70% of the stock is owned by corporate insiders.

Heartflow Stock Up 4.6%

NASDAQ:HTFL opened at $46.69 on Friday. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $60.65. The stock’s 50 day simple moving average is $51.76 and its two-hundred day simple moving average is $35.64.

Heartflow (NASDAQ:HTFL – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.15. Heartflow had a negative return on equity of 20.53% and a negative net margin of 33.11%. The firm had revenue of $72.86 million during the quarter. During the same quarter in the prior year, the company posted ($0.27) earnings per share. Analysts expect that Heartflow, Inc. will post -0.75 EPS for the current year.

Heartflow News Roundup

These are some of the HTFL news items that stood out recently:

  • Positive Sentiment: A report headline says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially signaling stronger growth expectations. The provided article text offers few details on the results. Article: HeartFlow Q2 revenue and guidance
  • Negative Sentiment: Recent coverage flagged insider share sales, including a transaction reported at about $4.2 million. Other reports describe Campbell Rogers’ sales, some made under pre-arranged Rule 10b5-1 plans. Insider selling can unsettle investors, although planned sales do not necessarily signal a change in the insider’s view of the company. Article: Heartflow insider sale
  • Negative Sentiment: Put-option trading rose sharply, with 6,628 puts traded—about 558% above the reported average. This may reflect increased demand for downside protection or bearish bets, though options activity alone does not establish investors’ outlook.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HTFL shares. Canaccord Genuity Group lifted their price objective on shares of Heartflow from $56.00 to $69.00 and gave the company a “buy” rating in a research report on Friday, November 13th. Wall Street Zen upgraded shares of Heartflow from a “hold” rating to a “buy” rating in a research report on Sunday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Heartflow in a research note on Wednesday, November 4th. Stifel Nicolaus raised their target price on shares of Heartflow from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, November 13th. Finally, Robert W. Baird lifted their price target on shares of Heartflow from $56.00 to $68.00 and gave the company an “outperform” rating in a report on Friday, November 13th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $60.12.

Read Our Latest Analysis on Heartflow

Heartflow Profile

(Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Further Reading

Want to see what other hedge funds are holding HTFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heartflow, Inc. (NASDAQ:HTFL – Free Report).

Institutional Ownership by Quarter for Heartflow (NASDAQ:HTFL)

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.